Analyst Reco. EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Market Closed - Deutsche Boerse AG Other stock markets 14:29:01 31/05/2024 BST			5-day change	1st Jan Change
9.69 ^EUR	-3.34%		-4.06%	-54.29%

05-08	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT
05-08	Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	05-08	MT
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	05-07	MT
Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	05-07	MT
Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	02-15	MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	01-22	MT
Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target	12-11	MT
Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating	12-07	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating	11-02	MT
Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20	11-02	MT
JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target	14/06/23	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating	19/05/23	MT
Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating	19/05/23	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating	11/11/22	MT
HC Wainwright Lifts Price Target on EyePoint Pharmaceuticals to $25 From $24, Reiterates Buy Rating	04/08/22	MT
Chardan Capital Initiates EyePoint Pharmaceuticals at Buy with $21 Price Target	07/07/22	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $75 From $22, Maintains Buy Rating	15/11/21	MT
Cowen Adjusts Price Target on EyePoint Pharmaceuticals to $35 From $25, Keeps Outperform Rating	15/11/21	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $24 From $15, Keeps Buy Rating	15/11/21	MT
EYEPOINT PHARMACEUTICALS : HC Wainwright Adjusts EyePoint Pharmaceuticals' Price Target to $15 From $16, Maintains Buy Rating	06/05/21	MT
EYEPOINT PHARMACEUTICALS : Cowen Starts EyePoint Pharmaceuticals at Outperform with $25 Price Target	01/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Analyst Reco.

Filters